Photodynamic Therapy and the Evolution of a Lung-Sparing Surgical Treatment for Mesothelioma

Friedberg, Joseph S.; Mick, Rosemarie; Culligan, Melissa; Stevenson, James P.; Fernandes, A.; Smith, Doug; Glatstein, Eli; Hahn, Stephen M.; Cengel, Keith A.

doi:10.1016/j.athoracsur.2011.02.062

Cited by 57 publications

(57 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A literature review evaluating reports in the last 10 years of outcomes after pleurectomy decortication demonstrates a median survival between 10 and 25 months (Table 1) (2,5,9,12,(16)(17)(18)(19)(20)(21)(22)(23)(24)(25). Thirty-day mortality was between 0.0-6.8% across all studies.…”

Section: Discussionmentioning

confidence: 99%

“…Previous studies have shown that volume of disease correlates with overall survival (7). In regards to mesothelioma, however, the literature varies regarding what constitutes an adequate or maximum cytoreduction (8)(9)(10)(11)(12). Although there exists a completeness of cytoreduction score (CCS) for peritoneal malignancies, there currently does not exist a CCS for mesothelioma.…”

Section: Definitions and Operative Goalsmentioning

confidence: 99%

See 1 more Smart Citation

Pleurectomy and decortication

Vlahu

Vigneswaran

2017

Ann. Transl. Med.

View full text Add to dashboard Cite

Pleurectomy and decortication (P/D) improve survival and quality of life in selected patients with malignant pleural mesothelioma. The operative procedure was not standardized until recently. The goal of the operation is to perform a macroscopic complete resection of the tumor. This often involves resection of the parietal and visceral pleura and invariably a partial or complete resection and prosthetic reconstruction of ipsilateral hemidiaphragm. We describe our operative planning and technique as well as outcomes of P/D reported in current literature.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Definitions and Operative Goalsmentioning

confidence: 99%

Pleurectomy and decortication

Vlahu

Vigneswaran

2017

Ann. Transl. Med.

View full text Add to dashboard Cite

show abstract

“…From 2005 to 2008, 38 patients with advanced MPM-37 AJCC stage III/IV (97%) and 24 N2 (63%)-underwent extended pleurectomy and decortication (EPD) and porfimer sodium-based PDT. The first 14 patients were part of a comparative study between either EPP or EPD combined with PDT that determined superior results in the EPD-PDT group and a switch to using EPD-PDT as the sole treatment strategy for subsequent studies at this institution (39). Surprisingly, MCR was achieved in 97% of patients despite the cohort comprising mostly of stage III/IV and N2 patients, demonstrating that EPD is an effective surgery-based treatment to achieve MCR.…”

Section: Pdtmentioning

confidence: 99%

Intraoperative adjuncts for malignant pleural mesothelioma

Chan

Sugarbaker

Burt

2017

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

Malignant pleural mesothelioma (MPM) is a rapidly fatal disease. Multimodality surgically based therapies may extend survival in select patients, however, local relapse after resection is common.Novel intraoperative adjunctive therapies including heated intraoperative chemotherapy (HIOC), heated intraoperative povidone-iodine (PVP-I), and photodynamic therapy (PDT) target micrometastatic disease and aim to improve local control. This review details the most recent studies and trials of HIOC, heated intraoperative PVP-I, and PDT, this aims to provide an update on some of the most promising intraoperative adjuncts for patients with MPM.Keywords: Malignant pleural mesothelioma (MPM); heated intraoperative chemotherapy (HIOC); heated intraoperative povidone-iodine (PVP-I); photodynamic therapy (PDT)

show abstract

“…Friedberg et al evaluated intraoperative photodynamic therapy (PDT) in patients who underwent macroscopic complete resection (14 with modified EPP, 14 with e-P/D) [54]. The pleurectomy plus PDT group had significantly better [55].…”

Section: Multimodality Therapymentioning

confidence: 99%

Current Issues in Malignant Pleural Mesothelioma Evaluation and Management

Stevenson

2014

The Oncologist

View full text Add to dashboard Cite

Malignant pleural mesothelioma (MPM) is an uncommon disease most often associated with occupational asbestos exposure and is steadily increasing in worldwide incidence. Patients typically present at an older age, with advanced clinical stage and other medical comorbidities, making management quite challenging. Despite great efforts, the prognosis of MPM remains poor, especially at progression after initial treatment. Macroscopic complete resection of MPM can be achieved through extrapleural pneumonectomy (EPP) or extended (ie, radical) pleurectomy (e‐P/D) in selected patients and can result in prolonged survival when incorporated into a multimodality approach. Given the morbidity associated with surgical resection of MPM, optimizing identification of appropriate patients is essential. Unfortunately, most patients are not candidates for EPP or e‐P/D due to advanced stage, age, and/or medical comorbidity. Pemetrexed and platinum combination chemotherapy has become the cornerstone of therapy for patients with unresectable disease because the combination is associated with improved survival and quality of life in treated patients. However, MPM eventually becomes resistant to initial therapy, and benefit to further lines of therapy has not been substantiated in randomized clinical trials. Translational research has provided exciting insights into tumorigenesis, biomarkers, and immune response in MPM, leading to the development of multiple novel therapeutic agents that are currently in clinical trials. These advances hold the promise of a new era in the treatment of MPM and suggest that this disease will not be left behind in the war on cancer.

show abstract

Photodynamic Therapy and the Evolution of a Lung-Sparing Surgical Treatment for Mesothelioma

Cited by 57 publications

References 14 publications

Pleurectomy and decortication

Pleurectomy and decortication

Intraoperative adjuncts for malignant pleural mesothelioma

Current Issues in Malignant Pleural Mesothelioma Evaluation and Management

Contact Info

Product

Resources

About